Categoria: Uncategorized

Catania, October 24, 2024 – Mimesis proudly participated in a significant event organized by the Observatory on Trends and Applications of Supercomputing. This gathering aimed to explore the transformative potential of supercomputing and its implications for the healthcare sector, particularly in computational medicine. Representing Mimesis, Martina Di Salvatore emphasized the critical role that advanced computational resources play in the field of in silico medicine. Mimesis, as a spin-off of the University of Catania, is dedicated to offering innovative solutions for the biomedical and pharmaceutical industries. Through the use of computational models, the company simulates the immune system’s behavior, enabling accurate responses in the context of various health challenges and therapies. Professor Francesco Pappalardo, a key figure in the company and co-leader of Spoke 8 ‘In Silico Medicine and Omics Data’ at the ICSC, highlighted how “in silico medicine is revolutionizing the research and development of new treatments, reducing drug development times and improving the precision of therapeutic interventions.” The event also featured the participation of other promising spin-offs from the University of Catania, as well as notable institutions like Ospedale Cannizzaro, showcasing the vibrant entrepreneurial ecosystem in the region. These organizations are leveraging advanced technologies to contribute to various sectors, highlighting the synergy between academic research and industry innovation. The gathering underscored the growing demand for supercomputing services, with projections indicating a significant increase in need by 2030. This surge presents substantial opportunities for companies that can harness advanced computational tools to drive innovation and enhance healthcare outcomes. As Mimesis continues to push the boundaries of computational medicine, it plays a vital role in shaping the future of healthcare in the region. The company is committed to advancing personalized medicine, aiming to streamline drug development processes and improve the precision of therapeutic interventions, ultimately benefiting patients and healthcare providers alike.

The In Silico World final event at the VPH2024 conference in Stuttgart was a landmark occasion, and the Mimesis group is thrilled to have been a key part of this groundbreaking event. With over 180 participants joining us both in person and virtually, the event provided a valuable platform to celebrate the advancements in #InSilicoMedicine and the collaborative achievements of our community. A standout moment of the conference was Prof. Pappalardo’s presentation, where he addressed the regulatory challenges facing in silico medicine and highlighted the significant progress made in navigating these barriers. His insights were instrumental in framing the current landscape and future directions for regulatory practices in our field. The Mimesis group was honored to showcase our innovative solutions and technological advancements, which represent the forefront of computational modeling and simulation in healthcare. Our work, presented alongside the COmbine group’s contributions, reflects the high level of innovation and dedication that has characterized the In Silico World project. Together, we are pioneering approaches that have the potential to revolutionize patient care through advanced predictive models and virtual simulations. We extend our deepest gratitude to all participants, contributors, and supporters who made this event a success. The collective effort and passion demonstrated by everyone involved have been truly inspiring. As we conclude the In Silico World project, we remain steadfast in our commitment to advancing #InSilicoMedicine and driving innovation in healthcare. At Mimesis, we are excited about the future and eager to continue pushing the boundaries of what’s possible in computational medicine. Our dedication to improving patient outcomes through innovative technologies will guide our efforts moving forward. We look forward to sharing more updates and continuing our journey toward transforming healthcare. Thank you to everyone who has been a part of this incredible endeavor. The future of in silico medicine is bright, and we are excited to continue this journey with our talented partners and the broader scientific community. Stay connected with Mimesis for more news and updates on our latest advancements in #InSilicoMedicine.

  Ieri, 11 luglio 2024, si è tenuto l’evento 🌟 𝐏𝐢𝐚𝐜𝐞𝐫𝐢 𝐃𝐚𝐲 𝟐𝟎𝟐𝟒 🌟, una giornata dedicata alla ricerca promossa dall’Università degli Studi di Catania (UNICT). Questo evento ha rappresentato una straordinaria opportunità per Mimesis S.r.l. e il nostro team di ricerca di condividere il nostro lavoro innovativo e i progressi compiuti nell’ambito delle simulazioni in silico. Un’opportunità unica per Mimesis Partecipare al Piaceri Day 2024 è stato un grande onore per noi. Durante la giornata, abbiamo avuto l’occasione di presentare i nostri progetti più recenti e di discutere le future direzioni del nostro lavoro con colleghi, accademici e altri professionisti del settore. Questo evento ci ha permesso di mettere in mostra le capacità e l’impegno del nostro gruppo di ricerca, nonché di tutto il Dipartimento di Scienze del Farmaco e della Salute dell’Università di Catania. Ringraziamenti e Prospettive Future Vogliamo ringraziare tutti coloro che hanno partecipato al Piaceri Day 2024 e che hanno contribuito a rendere questa giornata un successo. Il supporto e l’interesse dimostrati nei confronti del nostro lavoro sono stati fonte di grande ispirazione per tutto il team di Mimesis. Guardando al futuro, siamo determinati a continuare a innovare e a sviluppare nuove tecnologie in grado di trasformare il panorama della salute e del benessere. Il Piaceri Day 2024 ha rappresentato un importante passo avanti nel nostro percorso e siamo entusiasti di vedere dove ci porteranno le nostre prossime ricerche. Rimanete sintonizzati per ulteriori aggiornamenti e per scoprire le prossime tappe del nostro viaggio!

We’re excited to share that our research team at the University of Catania is front and center in #UnictMagazine with our latest groundbreaking study on the #JollyVaccine! In this pioneering investigation, we’ve dedicated ourselves to crafting an innovative solution to address the complexities surrounding vaccination, specifically focusing on the concept of a “Jolly Vaccine.” This initiative has garnered attention from both within and outside the scientific community, as it holds the promise of significantly advancing preventive medicine. Our methodology integrates state-of-the-art technologies with a profound understanding of immunological science, with the goal of surpassing the limitations associated with conventional seasonal vaccines. The #JollyVaccine aims to provide broader and longer-lasting protection against a diverse array of pathogens, thereby enabling enhanced adaptability in managing health crises and bolstering resilience against potential future threats. This study underscores the University of Catania’s unwavering commitment to fostering innovation and excellence in scientific inquiry, thereby contributing to global well-being and health security. We extend our gratitude to all who have supported and contributed to this achievement, and we eagerly anticipate sharing further updates on the progress of our research. Here’s the link to the article: https://www.unictmagazine.unict.it/simulare-il-sistema-immunitario-sviluppare-un-vaccino-influenzale-universale?fbclid=IwAR2eVfK8qrGGn1spHqbnE1m4QFHUu3-5VFHLA3lc5OjwnsYL6PaR1UbBEsg&sfnsn=scwspwa

OMS World Patient Safety Day and Mimesis Srl: an interview. 17 September marks the 5th World Patient Safety Day (WPSD), promoted by the World Health Organization (WHO) whose theme this year will be ‘Safe Medication’ related to the global campaign ‘Medication without Harm’. The aim of this day is to raise awareness of the impact that medication errors and unsafe practices can have on the patient, emphasizing the need for urgent action to improve the safety of the medication pathway and, consequently, the safety of the patient himself. It is in this context that Mimesis SRL acts, an innovative start-up in the medical-scientific field born in 2020 as a spin-off of the University of Catania. The work of Mimesis is fundamentally based on reproducing phenomena of a structural-chemical-biological nature through In Silico technology, i.e. through the use of computational models capable of almost completely reproducing the general behaviour of the immune system, and simulating its responses both in the presence of viruses, bacteria, tumors and autoimmune diseases, and in the presence of pharmacological therapies. It is therefore clear that, thanks to this approach, which does not involve the use of humans in the experimental stages of research, patient safety is almost completely guaranteed. We met Professor Francesco Pappalardo and Dr Giulia Russo, founders of the company, to discuss the issue of patient safety applied to their research. Professor Francesco Pappalardo is Associate Professor of Informatics at the Department of Pharmaceutical and Health Sciences at the University of Catania, where he also holds the position of Deputy Director of the Department. In addition, since 2016, he is Visiting Professor at the Boston University and Health Informatics Research Lab, Computer Science Department and Adjunct Professor at University of Griffith, Australia. Dr Giulia Russo gained her PhD in “Basic and Applied Biomedical Sciences” in 2018 with a special interest in computational and systems biology topics. From 2018 to 2020 she was a Research Fellow at the Department of Pharmaceutical and Health Sciences, University of Catania. Since 2020 she has been a Research Fellow in Computer Science at the same Department. She also teaches Computer Science at the CdLM in Pharmacy of the University of Catania and she is Adjunct Research Fellow at University of Griffith, Australia. Good morning to you. Before we begin, can you briefly introduce yourselves? F-Good morning, I am Francesco Pappalardo. I am an Associate Professor at the Department of Pharmaceutical and Health Sciences at the University of Catania, where I also hold the position of Deputy Director of the Department. I am also Adjunct Professor at Boston University in the United States and Griffith University in Australia. G-Hello everyone. My name is Giulia Russo. I teach Computer Science at the CdLM in Pharmacy of the University of Catania and I am a Chief Research Officer at MIMESIS. I am also holding a position of Adjunct Research Fellow at University of Griffith, Australia. What does your research consist of and what diseases do you focus on? Our research consists of the development and implementation of an in silico platform, the Universal Immune System Simulator (UISS), which simulates the immune system in order to observe the course of specific diseases and their treatments, and to predict the immune response towards a pathogen and/or a therapy. We are mainly focused on infectious disease, such as tuberculosis, COVID-19, or on tumors, such as mammary carcinoma, or on autoimmune disease, such as multiple sclerosis. For the latter we are developing a M&S platform able to predict the outcome of a disease: using a digital patient, created from a set of features, the M&S platform can represent the real one and, therefore, it can modify the therapy selecting the one that has the best therapeutic effect. M&S is also going to speed up the drug discovery pipeline and it can provide strong and formal tools to assess credibility and uncertainty quantification of M&S applied to healthcare. What does MIMESIS offer? MIMESIS is an innovative startup and spin-off of the University of Catania that applies computational models to the pharmaceutical/nutraceutical sector, allowing the simulation of phenomena of a structural-chemical-biological nature.Mimesis offers the first generation of “In Silico” solutions to the biomedical industry and pharmaceutical companies to reduce time and costs in the research and development process of medicinal products. What are the results obtained so far?And the benefits for the patients? Thanks to the In Silico technology we are able to predict the best treatment regimen for the patient profile of interest. We have drastically reduced the number of in vivo experiments, which means significant cost savings; we are also able to provide a better prediction of the toxicity profile of medical products, which means almost completely avoiding severe side effects. These technologies and methodologies can make ad-personam therapies available for everyone, despite differences in income, social status, living country, race, and cultural origins. Can we therefore say that in silico technology will be able to predict the effects of long-term therapy on patients with serious diseases? Modelling and simulation can speed up the development of new therapies and, at the same time, predict, almost completely, their outcomes on a patient: we believe, therefore, that the effects of a therapy can be predicted even in the long term. One last question: what future do you foresee for in silico research? Today, the healthcare industry faces many challenges: one of the most important is the pandemic emergency, so the need to adopt these new technologies is increasing. We believe that in silico technology can accelerate and optimize the pharmaceutical device discovery process and, consequently, lower production costs. Furthermore, the use of virtual patients has made it possible to almost completely eliminate the use of humans, thus demonstrating that it cares about ethics. We are convinced that, in this extraordinary multidisciplinary context in which in silico medicine operates, everything can be powerful and possible! Thank you. Italian Version Il 17 settembre ricorre la V° giornata internazionale sulla sicurezza dei pazienti (WPSD), promossa dall’Organizzazione Mondiale della Sanità (OMS) il cui tema …

Leggi tutto “OMS World Patient Safety Day and Mimesis Srl: an interview.”